FDA Drug Recalls

Recalls / Class III

Class IIID-1327-2015

Product

Hydralazine Hydrochloride Injection, USP, 20 mg/mL, 1 mL fill, in a 2 mL; single dose vial. Manufactured by Fresenius Kabi USA 2020 N Ruby Street, Melrose Park, IL 60160-1112 for Fresenius Kabi USA, 3 Corporate Dr Lake Zurich, IL 60047-8930. NDC 63323-614-01

Brand name
Hydralazine Hydrochloride
Generic name
Hydralazine Hydrochloride
Active ingredient
Hydralazine Hydrochloride
Route
Intramuscular, Intravenous
NDC
63323-614
FDA application
ANDA040388
Affected lot / code info
Lot #: 6110593, Exp 11/2016

Why it was recalled

Incorrect Expiration Date: The "11/06" expiration date printed on the tray (secondary packaging) is incorrect (it should be 11/2016)

Recalling firm

Firm
Fresenius Kabi USA, LLC
Notification channel
Letter
Type
Voluntary: Firm initiated
Address
3 Corporate Dr, N/A, Lake Zurich, Illinois 60047-8930

Distribution

Quantity
93,000 vials
Distribution pattern
Nationwide

Timeline

Recall initiated
2015-07-28
FDA classified
2015-08-12
Posted by FDA
2015-08-19
Terminated
2016-03-08
Status
Terminated

Source: openFDA Drug Enforcement endpoint. Recall record D-1327-2015. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.

Class III recall: Hydralazine Hydrochloride · FDA Drug Recalls